Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

(1) Background: The European Association of Urology (EAU) biochemical recurrence (BCR) risk grouping relies on data from historical cohorts that used conventional imaging techniques. In the era of PSMA PET/CT, we compared the patterns of positivity in the two risk groups and provided insight into positivity predictive factors. (2) Methods: Data from 1185 patients who underwent Ga-PSMA-11PET/CT for BCR was analyzed, out of which 435 patients treated initially treated by radical prostatectomy were included in the final analysis. (3) Results: A significantly higher rate of positivity in the BCR high-risk group was observed (59% vs. 36%, < 0.001). BCR low-risk group demonstrated more local (26% vs. 6%, < 0.001) and oligometastatic (100% vs. 81%, < 0.001) recurrences. The BCR risk group and PSA level at the time of PSMA PET/CT were independent predictive factors of positivity. (4) Conclusions: This study confirms that the EAU BCR risk groups have different rates of PSMA PET/CT positivity. Even with a lower rate in the BCR low-risk group, oligometastatic disease was 100% in those with distant metastases. Given the presence of discordant positivity and risk classification, integrating PSMA PET/CT positivity predictors into risk calculators for BCR might improve patient classification for subsequent treatment options. Future prospective studies are still needed to validate the above findings and assumptions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252094PMC
http://dx.doi.org/10.3390/cancers15112926DOI Listing

Publication Analysis

Top Keywords

psma pet/ct
16
risk groups
12
bcr risk
12
european association
8
association urology
8
biochemical recurrence
8
radical prostatectomy
8
bcr
8
positivity risk
8
predictive factors
8

Similar Publications

PET/CT in breast cancer.

Rev Esp Med Nucl Imagen Mol (Engl Ed)

September 2025

Servicio de Medicina Nuclear, Clínica Universidad de Navarra, Madrid, Spain; Grupo de Trabajo de Oncología de la SEMNIM, Spain.

Breast cancer is one of the most prevalent neoplasms worldwide, with molecular subtypes that influence prognosis and therapeutic strategies. PET/CT with different radiopharmaceuticals has revolutionized diagnosis, staging, and treatment monitoring. [F]-Fluorodeoxyglucose remains the most widely used radiotracer, but it has limitations in certain subtypes, such as invasive lobular carcinoma, where 16α-[F] fluoro-17β-estradiol and [Ga]-FAPI (fibroblast activation protein inhibitors) have demonstrated greater utility.

View Article and Find Full Text PDF

Silicon-based ligands are of interest in increasingly used Prostate-specific membrane antigen (PSMA) tracers for prostate cancer (PCa) staging due to their simple and scalable production. Here, we present first data on dosimetry and biodistribution of the novel PSMA-specific tracer [¹⁸F]siPSMA-14.Seven PCa patients referred for PSMA-PET/CT imaging were imaged at 60 and 120 min p.

View Article and Find Full Text PDF

Background: Intermediate-risk prostate cancer (IR-PC) represents a heterogeneous group requiring nuanced treatment approaches, and recent advancements in radiotherapy (RT), androgen deprivation therapy (ADT), and prostate-specific membrane antigen positron emission tomography (PSMA-PET/CT) imaging have prompted growing interest in personalized, risk-adapted management strategies. This study by the Turkish Society for Radiation Oncology aims to examine radiation oncologists' practices in managing IR-PC, focusing on RT and imaging modalities to identify trends for personalized treatments.

Methods: A cross-sectional survey was conducted among Turkish radiation oncologists treating at least 50 prostate cancer (PC) cases annually.

View Article and Find Full Text PDF

Purpose: Despite the effectiveness of [Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC), hematologic toxicity remains a concern, particularly in patients with bone metastases. This study evaluated whether the extent, intensity, and heterogeneity of bone disease on pretreatment PSMA-PET/CT were associated with hematologic toxicity, PSA response, and overall survival (OS) in mCRPC patients treated with [Lu]Lu-PSMA-617.

Methods: This retrospective study included 96 mCRPC patients who underwent pretreatment PSMA-PET/CT and received standard-of-care [Lu]Lu-PSMA-617.

View Article and Find Full Text PDF

Predictive Value of Metastatic Distribution Patterns on [Ga]Ga-PSMA PET/CT for [Lu]Lu-PSMA Therapy.

Rev Esp Med Nucl Imagen Mol (Engl Ed)

September 2025

Department of Biostatistics, Gaziantep University, Gaziantep, Turkey.

Objective: This study aimed to assess the predictive value of metastatic distribution patterns on Ga-PSMA-11 PET/CT in patients with chemotherapy- and castration-resistant prostate cancer undergoing ¹⁷⁷Lu-PSMA-617 radioligand therapy.

Materials And Methods: A retrospective analysis was conducted on 48 patients who received ¹⁷⁷Lu-PSMA-617 therapy between April 2019 and August 2023. Demographic, clinical, and laboratory data, along with pre- and post-treatment Ga-PSMA-11 PET/CT images, were evaluated for associations with molecular response and progression.

View Article and Find Full Text PDF